{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:15:31Z","timestamp":1792818931605,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.semarthrit.2024.152461","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:40:06Z","timestamp":1715953206000},"page":"152461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-100X","authenticated-orcid":false,"given":"Adam","family":"Goldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bat-El Lugassy","family":"Galper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Druyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chagai","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassem","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liran","family":"Shechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Moshkovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Ben-Zvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2024.152461_bib0001","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.semarthrit.2024.152461_bib0002","first-page":"2377","volume":"370","author":"Lee","year":"2014"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152461_bib0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152461_bib0004","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152461_bib0005","unstructured":"Janus kinase (JAK) inhibitors: drug safety communication - FDA Requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death, FDA. 2021. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed May 25, 2022."},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152461_bib0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152461_bib0007","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","article-title":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study","volume":"61","author":"Desai","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152461_bib0008","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152461_bib0009","first-page":"1130","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152461_bib0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152461_bib0011","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152461_bib0012","unstructured":"FDA adverse event reporting system (FAERS) public dashboard, FDA. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed July 25, 2022."},{"key":"10.1016\/j.semarthrit.2024.152461_bib0013","doi-asserted-by":"crossref","DOI":"10.5772\/50095","article-title":"Data Mining Techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi","year":"2012","journal-title":"Data Mining Applications in Engineering and Medicine"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152461_bib0014","first-page":"65","article-title":"MedDRA: An overview of the medical dictionary for regulatory activities","volume":"23","author":"Mozzicato","year":"2009","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.semarthrit.2024.152461_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA queries: their role in signal detection","volume":"30","author":"Mozzicato","year":"2007","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152461_bib0016","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152461_bib0017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152461_bib0018","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152461_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152461_bib0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","article-title":"Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis","volume":"5","author":"Cohen","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152461_bib0021","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10188","key":"10.1016\/j.semarthrit.2024.152461_bib0022","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.semarthrit.2024.152461_bib0023","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.semarthrit.2024.152461_bib0024","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152461_bib0025","series-title":"A study of baricitinib (LY3009104) in participants with rheumatoid arthritis (RA-BRIDGE)","author":"Lilly","year":"2019"},{"key":"10.1016\/j.semarthrit.2024.152461_bib0026","series-title":"A study of baricitinib in participants with rheumatoid arthritis (RA-BRANCH)","author":"Lilly","year":"2019"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152461_bib0027","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152461_bib0029","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152461_bib0030","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152461_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152461_bib0032","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","article-title":"Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: a retrospective, pharmacovigilance study","volume":"16","author":"Goldman","year":"2021","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152461_bib0033","first-page":"804","article-title":"Autoimmune diseases and new-onset atrial fibrillation: a UK Biobank study","volume":"25","author":"Tilly","year":"2023","journal-title":"EP Eur"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152461_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152461_bib0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the united states food and drug administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152461_bib0036","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.semarthrit.2024.152461_bib0037","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","article-title":"Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases","volume":"134","author":"Khouri","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152461_bib0038","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","article-title":"The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265\u200975 years): a retrospective, pharmacovigilance study","volume":"22","author":"Goldman","year":"2023","journal-title":"Cardiovasc Diabetol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:46:51Z","timestamp":1720046811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722400101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"alternative-id":["S004901722400101X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152461","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152461"}}